/
Advances in the Treatment of Advances in the Treatment of

Advances in the Treatment of - PowerPoint Presentation

danika-pritchard
danika-pritchard . @danika-pritchard
Follow
347 views
Uploaded On 2018-11-05

Advances in the Treatment of - PPT Presentation

HCV Genotype 3 and HIVHCV Coinfection Whats So Special About HCVGT3 Infection Why Talk About HIVHCV Coinfection ALLY3 Study ALLY3 cont Daclatasvir Sofosbuvir for 12 Weeks ALLY3 Study ID: 715409

cont hcv study ally hcv cont ally study weeks hiv coinfection sofosbuvir real world astral multicenter analysis compassionate french

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Advances in the Treatment of" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection Slide2
Slide3
Slide4
Slide5

What's So "Special" About HCV-GT3 Infection?Slide6

Why Talk About HIV/HCV Coinfection?Slide7

ALLY-3 StudySlide8

ALLY-3 (cont)Daclatasvir + Sofosbuvir for 12 WeeksSlide9

ALLY-3+ StudyDaclatasvir + Sofosbuvir + Ribavirin for 12 or 16 Weeks in Patients With Advanced Fibrosis or Cirrhosis Infected With HCV-GT3Slide10

ALLY-3+ Study (cont) Slide11

ALLY-3+ Study, contSlide12

ASTRAL-3 StudySofosbuvir/VelpatasvirSlide13

ASTRAL-3 Study (cont)Slide14

ASTRAL-3 Study (cont)Slide15

Real-World DataHow Effective and Safe Are These Regimens in Clinical Practice?Slide16

French Multicenter Compassionate Use Program Interim AnalysisSlide17

French Multicenter Compassionate Use Program Interim Analysis (cont)Slide18

European Multicenter Compassionate Use ProgramInterim AnalysisSlide19

Back to the Ribavirin QuestionSlide20

ALLY-2Daclatasvir/SofosbuvirSlide21

Rethinking HIV/HCV CoinfectionAre the Results Really As Good As for HCV Monoinfection?Slide22

GECCO: Real-World DataSofosbuvir/Ledipasvir for 8 WeeksSlide23

Sofosbuvir/Daclatasvir In Patients With HIV/HCV Coinfection and Advanced Liver DiseaseA Real-World TrialSlide24

C-EDGEGrazoprevir/Elbasvir for 12 Weeks in HCV-GT1, 4, 6Slide25

C-EDGE, contEvaluated Outcomes In Monoinfection and CoinfectionSlide26

C-EDGE, contGrazoprevir/Elbasvir for 12 Weeks in HCV-GT1, 4, 6Slide27

SummarySlide28

AbbreviationsSlide29

Abbreviations (cont)